High hopes for AngioChem's brain cancer drug candidate
This article was originally published in Scrip
Executive Summary
The Canadian company AngioChem is expecting lots of interest from healthcare professionals and potential partners when it presents data on its lead compound, ANG1005, a chemotherapy drug, for the treatment of brain cancers at the Society for Neuroscience annual meeting in Chicago next week.